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Introduction
It is important to remember why this de-
bate is taking place. Prior to 1985 ‘intui-
tive reasoning’ dominated decision-mak-
ing with senior surgeons determining in-
vestigative and therapeutic strategies with 
little regard for evidence (or risk). A ‘tip-
ping point’ occurred in the mid-1980s re-
garding the optimal management of pa-
tients with symptomatic carotid disease. 
As far as neurologists (of the time) were 
concerned surgeons had no accountabil-
ity, undertook no meaningful audit, pub-
lished implausibly good results, were 
largely unwilling to participate in clinical 
trials and were responsible for huge in-
creases in carotid endarterectomy (CEA) 
numbers, regardless of appropriateness. 
The gulf between surgeons and neurol-
ogists was highlighted in a Rand Corpo-
ration report, which showed that (fol-
lowing independent review), the indica-
tion for 65 % of Medicare patients under-
going CEA in 1981 was deemed ‘uncer-
tain’ or ‘inappropriate’. To make matters 
worse, these patients incurred a 9.5 % risk 
of death or stroke following surgery [1].
Charles Warlow, an arch-opponent 
of ‘intuitive reasoning’ and soon to be-
come principle investigator of the Euro-
pean Carotid Surgery Trial (ECST [2]), 
opined that “surgeons concluded that 
CEA was of value because they: (i) ig-
nored minor peri-op strokes, (ii) used 
the worst possible natural history studies 
for comparison and (iii) did not include 
strokes following angiography” when jus-
tifying a role for CEA. It would be fair to 
say that many surgeons (of that era) dis-
agreed with his opinion and were high-
ly suspicious of neurologists’ motives and 
were (to a large part) hostile to using ran-
domized controlled trials (RCTs) to de-
termine ‘best practice’. In short, surgeons 
believed that the neurologists were sim-
ply out to stop them from operating. Par-
adoxically, however, the very fact that a 
sufficiently large number of enlightened 
surgeons and neurologists on both sides 
of the Atlantic, thereafter participated in 
the two landmark RCTs in symptomatic 
patients was actually to become the sav-
ior of the operation. Without the ECST 
and the North American Symptomatic 
Carotid Endarterectomy Trial (NASCET 
[3]), CEA would never have risen to the 
universally accepted position that it cur-
rently holds. Not surprisingly, vascular 
surgeons quickly embraced the move to-
wards evidence-based medicine (EBM), 
having seen how it had finally rid them 
of those ‘troublesome neurologists’. Since 
then, RCTs have been used in the evalu-
ation of a large number of cardiovascular 
treatments, to the extent that many con-
temporary surgeons cannot remember 
(would not know) just how bad the pre-
RCT days really were. The current prob-
lem, however, is that RCTs (themselves) 
are becoming a target for increasing crit-
icism, as a growing body of clinicians ar-
gue for a return to using observational 
studies and registries to determine opti-
mal practice.
What is evidence-based 
medicine?
The ultimate goal of EBM is the delivery 
of optimal clinical care to patients, based 
upon the following tenets: (i) the accumu-
lation of evidence through research and 
scientific review, (ii) the preparation and 
dissemination of evidence-based clinical 
guidelines, (iii) active implementation of 
evidence-based clinical practice and (iv) 
subsequent audits to see how closely ‘re-
al world’ practice mirrors that of the sup-
porting RCT evidence [4]. In addition, 
in a world of increasing cost constraints, 
EBM is seen as a means of controlling ex-
penditure. Central to EBM is how the sci-
entific evidence is gathered and this is 
where much of the debate now lies. Put 
simply, should EBM rely primarily on 
RCT data (as it has done since the 1980s) 
or might there now be an increasing role 
for observational studies or other innova-
tive research strategies?
Observational studies
It is reasonable to concede that the ob-
servational studies of the pre-ECST/NA-
SCET era bear little methodological re-
semblance to those of the current era. Ob-
servational studies do not randomize pa-
tients but they do ‘observe’ or document 
differences in outcomes after manage-
ment decisions have been made [5]. Ob-
servational studies are often used to eval-
uate the effectiveness of an intervention 
in the ‘real world’, especially in popula-
tions that are under-represented in RCTs 
(e.g. the elderly, ethnic minorities, wom-
en, low socioeconomic status and multi-
ple comorbidities) [6]. They are also use-
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ful for formulating hypotheses that can 
then be tested in future RCTs, for deter-
mining sample sizes and for identifying 
patient subgroups which might benefit 
from alternative treatment strategies [5].
Observational studies are, howev-
er, limited by the fact that ‘experimen-
tal groups’ and ‘control groups’ are not 
matched for patient characteristics (i.e. 
there is considerable potential for selec-
tion bias). Unless carefully designed, it 
can be difficult to separate effects attrib-
uted to the new treatment under inves-
tigation from other confounding factors, 
which may or may not have been equally/
unequally distributed between the exper-
imental and control groups. In addition, 
whilst administrative datasets may pro-
vide large numbers of patients for study, 
they often do not contain sufficient de-
tail regarding comorbidities etc. to allow 
risk stratification and meaningful statisti-
cal evaluation. However, notwithstanding 
these methodological limitations, RCTs 
cannot always be undertaken (evidence 
for developing clinical guidelines in rare 
clinical conditions has to come from ob-
servational studies) and it should be rec-
ognized that observational studies have 
been responsible for discovering causal 
associations between smoking and lung 
cancer, asbestos with mesothelioma and 
thalidomide with birth defects.
Randomized controlled trials
The fundamental advantage of the RCT is 
its excellent ‘internal validity’. This means 
that because all trial participants are ran-
domized, selection bias is greatly mini-
mized in the hope that the only difference 
between the treatment arms is their expo-
sure to the management strategy under in-
vestigation [6]. Reducing or abolishing se-
lection bias then enables more statistical-
ly robust analyses; however, whilst RCTs 
have been integral in determining opti-
mal practice in the management of vas-
cular patients with symptomatic (asymp-
tomatic) carotid disease and for endovas-
cular aneurysm repair (EVAR), there is a 
growing concern that RCTs have failed to 
guide more contemporary clinical practic-
es. For example, 13 RCTs have now com-
pared CEA with carotid artery stenting 
(CAS) with little evidence of consensus; 
however, many of the flaws or failings in 
recent RCTs were mostly self-inflicted and 
should have been anticipated and/or cor-
rected during the planning phase. In ret-
rospect, ECST and NASCET ‘worked’ be-
cause they addressed a simple question 
(comparing two long-established treat-
ment strategies), a sufficiently large num-
ber of surgeons and neurologists recog-
nized the need to commit to such a tri-
al and both trials were sufficiently pow-
ered to answer the question posed and al-
so enable clinically meaningful subgroup 
analyses [7, 8].
Unfortunately, the ‘knee-jerk’ response 
to any contemporary clinical problem is to 
immediately demand that a randomized 
trial be performed (usually by a clinical 
specialty under threat) and this has led 
to a proliferation of underpowered, un-
derfunded and ill-thought-out RCTs. Ac-
cordingly, it has become much too easy to 
simply ‘shoot the RCT messenger’ rather 
than address the underlying methodologi-
cal problems. Put simply, if an RCT (or in-
deed any observational study) is designed 
badly, do not be surprised if it becomes 
‘part of the problem’.
Observational studies 
versus RCTs?
Meta-analyses of observational 
study versus RCT data
As a consequence of the problems asso-
ciated with observational studies preced-
ing the ECST/NASCET in 1991, it is still 
intuitively believed that observational 
studies are methodologically inferior to 
RCTs; however, large scale ‘meta-analyses 
of meta-analyses’ have observed that this 
assumption may be ill-founded. In a 2014 
Cochrane review, which analyzed the re-
sults of healthcare outcomes obtained us-
ing observational study designs compared 
with those obtained from RCTs, Angle-
myer et al. identified 14 reviews with da-
ta from 1583 meta-analyses, covering 
228 different medical conditions with 
the mean number of studies included in 
each meta-analysis being 178 [9]. The Co-
chrane review concluded that “there was 
little evidence for significant effect esti-
mate differences between observational 
studies and RCTs”. In addition, they ob-
served that “factors other than study de-
sign per se needed to be considered when 
exploring reasons for a lack of agreement 
between results of RCTs and observation-
al studies, especially levels of heterogene-
ity in meta-analyses of RCTs or observa-
tional studies”.
When have observational findings 
been reversed following RCTs?
Notwithstanding the findings of the 2014 
Cochrane review (and before everyone as-
sumes that observational studies should 
immediately replace all RCTs), it is im-
portant to remember that history is lit-
tered with examples of where observa-
tional studies suggested an important 
clinical benefit, only for it to be proved 
false following publication of an RCT. 
An extensive list of these has been high-
lighted by Rothwell [10] including high-
dose oxygen therapy in neonates, antiar-
rhythmic drugs after myocardial infarc-
tion, fluoride treatment for osteoporosis, 
bed rest in twin pregnancies, hormone re-
placement therapy in preventing throm-
botic cardiovascular disease, extracranial 
to intracranial arterial bypass surgery for 
 stroke prevention in patients with a ca-
rotid occlusion, high-dose aspirin therapy 
prior to CEA and digoxin after myocar-
dial infarction. To these can also be add-
ed bone marrow transplantation for the 
treatment of breast cancer, in the SAMM-
PRIS trial (which showed no evidence of 
benefit for intracranial stenting over med-
ical therapy alone in patients with recent 
neurological symptoms and intracrani-
al disease) [11] and the GALA trial [12]. 
The GALA trial is an important example 
of this phenomenon. A meta-analysis of 
41 observational studies (25,000 CEAs) re-
ported that CEA under locoregional an-
esthesia was associated with a 40 % rela-
tive risk reduction in perioperative stroke/
death compared to CEA patients using 
general anesthesia, as well as significant 
reductions in myocardial infarction (MI) 
and pulmonary complications [13]. How-
ever, a 2013 Cochrane review subsequent-
ly analyzed data from GALA and 13 oth-
er RCTs (4596 patients) and found no ev-
idence that the type of anesthesia influ-
enced perioperative outcomes [14].
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Why do discrepancies occur?
According to Hannan [5] most discrep-
ancies between observational studies and 
RCTs can be attributed to one or more 
problems relating to: (i) selection bias  
(less of a problem with RCTs because of 
the randomization process) which is a ma-
jor problem for observational studies. The 
latter can, however, be reduced by care-
ful risk adjustment through regression or 
propensity scoring: (ii) problems with gen-
eralizability. All RCTs have very strict in-
clusion and exclusion criteria (which pre-
vents selection bias and thus increases in-
ternal validity) but the findings may not 
be applicable to a much broader popula-
tion (i.e. RCTs can lack external validity). 
This problem will be further compound-
ed if RCTs were undertaken in large, ac-
ademic hospitals by highly experienced 
clinicians, if the majority of procedures 
are actually done by less experienced cli-
nicians in smaller institutions. Paradoxi-
cally, observational studies have greater 
external validity, as they tend to be more 
representative of ‘real world’ practice: (iii) 
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Abstract
Prior to the introduction of evidence-based 
medicine, decision-making was largely based 
upon ‘intuitive reasoning’, whereby senior cli-
nicians dictated practice based upon per-
sonal dogma, personal experience and (of-
ten) biased observational studies. This era 
began to end (in vascular surgery) follow-
ing completion of the landmark randomized 
trials in carotid disease, which recruited pa-
tients throughout the 1980s. Despite scep-
ticism amongst some surgeons of the time 
these particular randomized trials have stood 
the test of time and remain the cornerstone 
of virtually every guideline of practice to this 
day. The carotid randomized trials became a 
beacon for using ‘evidence’ rather than ‘intu-
itive reasoning’ and randomized trials have 
now been used to determine optimal prac-
tice in a plethora of carotid surgery and stent-
ing trials, lower limb revascularization and 
numerous aortic aneurysm based studies.
The literature abounds with situations 
where practice (previously based on obser-
vational study data) was changed overnight 
following publication of a well-designed ran-
domized trial. However, while observation-
al studies are prone to selection bias, ran-
domized trials bring their own unique limita-
tions including problems with external valid-
ity, they take too long to complete, they are 
very expensive, they are notorious for prob-
lems with recruitment and they can frequent-
ly become obsolete. This has led to a (not un-
reasonable) call for more observational stud-
ies to be used in the development of prac-
tice guidelines. Unfortunately, the principle 
guideline bodies around the world, e.g. Na-
tional Institute for Health and Care Excellence 
(NICE) and the American Heart Association 
(AHA), prioritize randomized trial evidence 
above all else. Until that changes, guide-
line makers will find it very difficult to devi-
ate from using historical randomized trial ev-
idence, even when high quality observation-
al data suggest that ‘real world’ practice bears 
little comparison to that reported in the ran-
domized trials. Nowhere is that more evident 
than in developing contemporary guidelines 
for the management of asymptomatic carot-
id disease.
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Randomisierte kontrollierte Studien: immer noch die Stütze der Gefäßchirurgie?
Zusammenfassung
Vor der Einführung der evidenzbasierten 
Medizin basierten Entscheidungen weit-
gehend auf Intuition, wobei die ärztlichen 
Vorgesetzten die praktische Vorgehens-
weise auf der Grundlage ihrer persönlichen 
Dogmen und Erfahrung sowie (oftmals) ver-
zerrter Beobachtungsstudien diktierten. 
Der Anfang vom Ende dieser Ära wurde 
eingeleitet durch den Abschluss der weg-
weisenden randomisierten Studien zu 
Karotiserkrankungen, für welche Patienten 
in den 1980er-Jahren rekrutiert wurden. 
Trotz der Skepsis mancher Chirurgen damals 
haben sich gerade diese randomisierten 
Studien bewährt und bilden bis heute 
immer noch den Grundpfeiler praktisch 
jeder Praxis-Leitlinie. Die randomisierten 
Studien zu Karotiserkrankungen wurden ein 
leuchtendes Beispiel für die Verwendung 
von „Evidenz“ statt „Intuition“, und seit-
dem werden randomisierte Studien zur Er-
mittlung des optimalen Vorgehens in einer 
Vielzahl von Studien zur Karotischirurgie, 
zur Stenteinlage, zur Revaskularisierung der 
unteren Extremität und in zahlreichen Unter-
suchungen zu Aortenaneurysmen eingesetzt.
Es finden sich in der Literatur viele Situ-
ationen, in denen die Praxis (die vorher auf 
Daten von Beobachtungsstudien beruhte) 
nach Publikation einer gut konzipierten ran-
domisierten Studie über Nacht geändert 
wurde. Während Beobachtungsstudien für 
eine Verzerrung durch Selektion anfällig sind, 
weisen randomisierte Studien jedoch eigene 
spezielle Limitationen auf, einschließlich 
Problemen mit externer Validität, langer 
Dauer bis zum Abschluss, hoher Kosten, der 
bekannten Schwierigkeiten bei der Rekrutier-
ung und dass sie dann häufig überholt sind. 
Das führte zu dem (nicht unverständlichen) 
Ruf danach, dass mehr Beobachtungsstu-
dien für die Entwicklung von Praxis-Leitli-
nien eingesetzt werden sollten. Leider geben 
überall auf der Welt die wesentlichen Leitli-
niengremien, z. B. das National Institute for 
Health and Care Excellence (NICE) und die 
American Heart Association (AHA) randomis-
ierten Studien den Vorzug vor allem anderen. 
Bis sich das ändert, werden die Entwickler 
von Leitlinien es sehr schwer haben, von der 
Verwendung von Evidenz aus historischen 
randomisierten Studien abzuweichen, selbst 
wenn Beobachtungsdaten hoher Qualität 
Hinweise darauf geben, dass die tatsächliche 
Praxis mit derjenigen, die in randomisierten 
Studien beschrieben wird, nur wenig gemein 
hat. Nirgendwo zeigt sich das deutlicher als 
bei der Entwicklung zeitgemäßer Leitlinien 
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inadequate statistical power. This is a cru-
cial problem. By their very nature, RCTs 
are expensive, they take a long time to re-
cruit and most usually randomize only a 
small minority of screened patients (0.5 % 
of patients undergoing CEA in North 
America in 1989 were randomized with-
in NASCET [15]).
Are RCTs always the 
perfect solution?
Absolutely not: RCTs work best when 
they are designed to answer an important 
(preferably simple) clinical question that 
has a clearly defined (and relevant) clin-
ical endpoint, which is adequately fund-
ed and where there is a realistic possibility 
of recruiting an adequate number of par-
ticipants in order for it to be adequately 
powered and externally valid. The prob-
lems (and there are many) arise when one 
or more of these caveats are compromised.
A number of examples of ‘failed’ or 
‘flawed’ RCTs in vascular/endovascular 
practice have been highlighted by Frank 
Veith [16]. Some of his criticisms are val-
id, some are open to interpretation, while 
some represent a triumph of ‘spin over re-
ality’. Examples include problems relat-
ing to: (i) one treatment under evaluation 
is still evolving. This has been a particu-
lar problem with the CEA vs CAS trials 
and it is conceded that this is a difficult 
issue to resolve, because most RCTs take 
a long time to meet ethical scrutiny and 
completion: (ii) there is an improvement in 
outcomes in the ‘control’ group. For exam-
ple, the recent reduction in annual stroke 
rates on medical therapy in asymptomat-
ic patients with carotid disease probably 
renders the landmark asymptomatic ran-
domized trials that were undertaken in 
the 1990s obsolete [17], raising the inev-
itable question as to whether they should 
be repeated: (iii) comparing highly experi-
enced practitioners in one treatment limb 
with less experienced practitioners in the 
other. This has been a particular criticism 
of the European RCTs comparing CEA 
with CAS but, on closer scrutiny, this is a 
classic example of ‘spin over substance’. In 
the French EVA-3S trial the highest com-
plication rates were observed in the most 
experienced CAS practitioners [18], while 
the most experienced centers in the ICSS 
study also incurred the highest procedural 
death/stroke rates [19]: (iv) imperfect ran-
domization strategies. This is largely a his-
torical problem but is especially relevant 
when a clinician can predict who will be 
randomized to each strategy (e.g. ran-
domizing by odd/even date or alternat-
ing weeks). This accusation has, howev-
er, also been leveled at the IMPROVE tri-
al [20] which randomized patients with a 
suspected ruptured abdominal aortic an-
eurysm (rAAA) before they underwent 
a confirmatory computed tomography 
(CT). This represents a pragmatic trial 
design strategy but the conclusions of the 
IMPROVE trial (i.e. no difference in early 
mortality rates between EVAR and open 
repair) were the same as those found in 
several other RCTs which only random-
ized patients after a diagnosis of rAAA 
was made and where the patients were 
deemed suitable for both EVAR and open 
repair [21, 22]. Meta-analyses of 1-year da-
ta from the three main European RCTs, 
however, now show a clinical and cost-
effectiveness benefit favoring EVAR [23] 
and it will be interesting to see whether 
the volume of criticism by EVAR advo-
cates now diminishes: (v) recruiting an in-
appropriate population. The classic exam-
ple of this is the SAPPHIRE trial, which 
randomized (predominantly asymptom-
atic) patients who were deemed at ‘high 
risk for CEA’ to undergo CAS or CEA. 
Perhaps not surprisingly, SAPPHIRE 
concluded that CAS was ‘not inferior’ 
to CEA [24]; however, the main conclu-
sion should have been that with the high 
complication rates observed, both treat-
ment groups would have been safer with 
medical therapy [25] and (vi) inappropri-
ate endpoints. This largely refers to the in-
clusion of non-standard composite end-
points (e.g. death/stroke/MI and/or tar-
get lesion revascularization) and surrogate 
markers. The inclusion of composite end-
points and surrogate markers are accept-
ed to be ‘softer endpoints’ and are includ-
ed in order to reduce the number of pa-
tients to be recruited (i.e. making the trial 
easier and cheaper to complete). The in-
clusion of ‘MI’ within the composite end-
point of perioperative death/stroke/MI 
in the CREST trial (comparing CEA vs. 
CAS) has been heavily criticized (usually 
by surgeons), because a subgroup analysis 
from CREST subsequently concluded that 
CAS was associated with a twofold reduc-
tion in perioperative MI, which was then 
associated with poorer long-term mortal-
ity rates [26]. In fact, while CEA was as-
sociated with a higher rate of periopera-
tive MI, a greater proportion of CAS pa-
tients suffering from a perioperative MI 
died prematurely [27], making this yet an-
other example of ‘spin over substance’.
To these methodological problems I 
would also add three others. First, is the 
impact of stopping an RCT too early. 
Stopped trials tend to happen on a ran-
dom ‘high’ or ‘low’ and they are not al-
ways abandoned with statistically robust 
supporting evidence. Second is the fact 
that a significant proportion of RCTs are 
completed but never written up. This re-
ally is a scandal. In a recent review, 81 out 
of 395 RCTs listed on ClinicalTrials.gov 
were discontinued early, usually because 
of problems with recruitment. Of the 79 % 
which went on to completion, there was a 
publication rate of only 66 % at a median 
of 5 years after study completion. Indus-
try sponsored RCTs were associated with 
lower odds of publication. This means 
that one in three completed RCTs went 
unpublished, thereby rendering it im-
possible for them to be included in sub-
sequent meta-analyses [28]. This will, of 
course, limit the overall external validity 
of the trials. Third is the failure to accept 
that sometimes RCTs pass their ‘sell by 
date’ and become obsolete. Unfortunate-
ly, because many guideline bodies priori-
tize RCT data (to the exclusion of almost 
everything else), this means that they con-
tinue to be (inappropriately) upheld as ex-
amples of level 1, grade A evidence.
What is the solution?
There is a very formalized and regulat-
ed structure for delivering new therapeu-
tic drugs into clinical practice. This is in 
marked contrast to surgical interventions, 
which have largely been ‘unregulated and 
unstructured’ [29]. According to the IDE-
AL group, ’surgical innovation lacks major 
commercial funding sources for research, 
partly because device, implant and tech-
nology developers do not have the barri-
ers to market entry as happens with drugs’ 
[29]. To address this (and also many of 
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the other points raised in this review), the 
IDEAL group has proposed a series of rec-
ommendations for evaluating surgical in-
novations. The principle phases are high-
lighted in . Table 1, which also indicates 
where roles for observational studies and 
RCTs might lie. As can be seen, the prin-
ciples are quite similar to that advocated 
in the past but there are some key areas 
of change. For example, the IDEAL group 
recognizes that not all interventions need 
to be subject to RCT comparison. A con-
temporary example of this might include 
open versus endovascular repair for trau-
matic aortic transection. The IDEAL 
group also offers alternatives to RCT com-
parison in those situations where an RCT 
is considered inappropriate or unethical. 
Second, is recognition that the ‘learning 
curve’ must be considered more careful-
ly during the planning phase of any RCT. 
Third, is a greater role for observation-
al studies and well-designed registries to 
audit practice in the ‘real world’ to ensure 
that outcomes achieved in RCTs are be-
ing replicated in the community at large.
Future developments
Prospective, randomized, 
controlled clinical registry trials
This is a new concept, pioneered by Swe-
den and other Scandinavian countries, 
whereby many of the practical and eco-
nomic problems associated with RCTs 
can be alleviated by incorporating them 
within established clinical registries [30]. 
The recently published Thrombus Aspi-
ration in ST Elevation MI in Scandinavia 
Trial (TASTE) is an excellent example of 
a new way of evaluating treatment strat-
egies. Fundamental to this concept is the 
presence of a high-quality, clinical reg-
istry, in this case the Swedish Coronary 
Angiography and Angioplasty Registry 
(SCAAR), which is based on social secu-
rity numbers and which has 100 % cover-
age of patients who remain in the coun-
try. It is funded by national health author-
ities (i.e. independent of industry) and of-
fers an on-line platform for randomiza-
tion, completion of case report forms and 
entering follow-up data (including those 
patients who declined to be randomized). 
In effect, the TASTE registry based RCT 
(i) combined the benefits of random-
ized treatment allocation as well as the 
best features of a large scale population 
based registry, (ii) it enabled broad inclu-
sion criteria to be used, such as chest pain, 
< 24 h of onset, electrocardiogram (ECG) 
evidence of ST elevation MI and require-
ment for primary coronary intervention 
(PCI), which meant that the findings were 
more likely to represent ‘real world prac-
tice’, (iii) it greatly reduced trial expendi-
ture and administration and (iv) enabled 
follow-up within an already existing reg-
istry structure.
The TASTE registry ultimately ran-
domized 60 % of the approximately 
12,000 patients presenting with an ST el-
evation MI undergoing PCI and showed 
that intracoronary thrombus aspiration 
before PCI did not reduce 30-day death/
stroke/recurrent MI or stent thrombosis 
[30]. This is a model that could be adopt-
ed for use in a number of vascular and en-
dovascular strategies in the future.
The importance of post-RCT 
surveillance in the community
A large amount of time, effort and mon-
ey is required to complete a RCT, yet there 
is little evidence that clinical governance 
ensures that ‘real world’ practices are safe 
and justifiable. An emerging example of 
this is the performance of CAS after the 
American Heart Association (AHA) lib-
eralized CAS indications in 2011 to in-
clude ‘average risk for CEA’ symptomat-
ic and asymptomatic patients [31]. The 
AHA recommended that CEA (CAS) be 
performed within centers with a 30-day 
death/stroke rate ≤ 6 % for symptomatic 
patients and ≤ 3 % for asymptomatic pa-
tients [31]; however, evidence from a re-
cent systematic review of outcome da-
ta from contemporary, large-volume ad-
ministrative datasets reporting outcomes 
following both CEA and CAS (predomi-
nantly from the USA), suggest that while 
CEA was performed with a procedural 
risk > 3 % in only 1 out of 15 registries in as-
ymptomatic patients, 9 out of 15 registries 
(60 %) reported death/stroke rates in ex-
cess of 3 % after CAS [32]. More worrying, 
while all 18 registries reported that CEA 
was performed with a mean death/stroke 
rate < 6 % in ‘average risk for CEA’ symp-
tomatic patients, 13 out of 18 registries 
(72 %) reported death/stroke rates > 6 %, 
while 5 out of 18 (28 %) reported death/
stroke rates > 10 % [32]. Not one of these 
registries commented that any of these 
risks were excessive or how poor perfor-
mance should be addressed [33].
Post-RCT surveillance of ‘real world’ 
outcomes is now a very important re-
quirement of the IDEAL recommenda-
tions (. Table 1) and examples of poor 
performance cannot be ignored any more. 
This is an ideal example of where obser-
vational studies and registries can rapidly 
Table 1 The ‘IDEAL’ recommendations for evaluating new interventionsa
Stage 1 New idea by a surgeon/interventionist Published as a ‘first in man’ case report
Stage 2a devel-
opment phase
Early report is positive and attracts 
early adopters. Focus is on technical 
development of the procedure




Investigation of indications, potential 
benefits and harms. During this phase, 
the early adopters refine their skills and 
move further up the learning curve
Prospective research databases (RDs) 
and OS to inform development of any 
RCT. Any decision on RCTs must recog-
nize the impact of any learning curve
Stage 3 assess-
ment phase
Key question posed: “is this technique 
better than the existing one”. If the op-
portunity for robust evaluation is not 
seized upon, widespread adoption may 
happen without evidence
RCTs should remain the default option. 
RCT may not be necessary if the advance 
CANNOT be explained by chance or bias. 
Alternatives to RCT include: parallel 
group non-RCTs, controlled interrupted 
time series studies ,step wedge designs, 




The procedure has become widely 
adopted. Essential to ensure that 
outcomes are audited and maintained 
within accepted standards. What is the 
level of external validity?
OS and registries with risk adjustment for 
patient comorbidities
aAdapted from McCulloch et al. [29].
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inform hospital providers and health ad-
ministrators as to whether their patients 
(as a whole) are receiving optimal care. 
Otherwise, there was little point in per-
forming the RCT in the first place.
Conclusion
It would be naïve to believe that the era 
of EBM is heading towards a decline; 
however, it is also naïve for advocates 
of using randomized trials to determine 
practice to ignore increasing problems 
relating to the development and perfor-
mance of randomized trials in the mod-
ern era. Guideline bodies must revise 
their methodology to recognize the im-
portance of well-performed observation-
al studies so that these too can be incor-
porated within contemporary guidelines.
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